Participants 73 126 3
after curative resection of hepatocellular carcinoma.
Participants 408 507 7
A prospective randomized controlled trial was conducted in patients with curative resection of HCC;
Participants 705 861 6
During a median follow up of 818 days, 21 patients received one dose and 19 received four doses, with 10 (47.6%) and eight (42.1%) recurrences, respectively
